中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

10 records (took 0.029 seconds)

    HUMAN ANTIGEN BINDING PROTEINS THAT BIND BETTA-KLOTHO, FGF RECEPTORS AND COMPLEXES THEREOF
    6.
    发明申请
    HUMAN ANTIGEN BINDING PROTEINS THAT BIND BETTA-KLOTHO, FGF RECEPTORS AND COMPLEXES THEREOF 审中-公开
    人类抗原结合蛋白，其包含KLOTHO，FGF受体及其复合物

    公开(公告)号：US20170015750A1

    公开(公告)日：2017-01-19

    申请号：US15280662

    申请日：2016-09-29

    Applicant: AMGEN INC.

    Inventor： Shaw-Fen Sylvia HU ,  Ian Nevin FOLTZ ,  Chadwick Terence KING ,  Yang LI ,  Taruna Arora

    IPC: C07K16/28

    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.

    Abstract translation: 本发明提供与抗原结合蛋白有关或衍生自抗原结合蛋白的组合物和方法激活FGF21介导的信号传导。 在实施方案中，抗原结合蛋白特异性结合（i）β-Klotho; （ii）FGFR1c，FGFR2c，FGFR3c或FGFR4; 或（iii）包含β-Klotho和FGFR1c，FGFR2c，FGFR3c和FGFR4之一的复合物。 在一些实施方案中，抗原结合蛋白诱导FGF21样信号传导。 在一些实施方案中，抗原结合蛋白是完全人，人源化或嵌合抗体，所述抗体的结合片段和衍生物，以及特异性结合（i）β-Klotho的多肽; （ii）FGFR1c，FGFR2c，FGFR3c或FGFR4; 或（iii）包含β-Klotho和FGFR1c，FGFR2c，FGFR3c和FGFR4之一的复合物。 其它实施方案提供了编码这种抗原结合蛋白的核酸及其片段和衍生物，以及多肽，包含这种多核苷酸的细胞，制备此类抗原结合蛋白的方法及其片段和衍生物以及多肽，以及使用这些抗原结合蛋白的方法 ，其片段及其衍生物和多肽，包括治疗或诊断患有2型糖尿病，肥胖症，NASH，代谢综合征和相关疾病或病症的受试者的方法。

    HUMAN ANTIGEN BINDING PROTEINS THAT BIND TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9
    7.
    发明申请
    HUMAN ANTIGEN BINDING PROTEINS THAT BIND TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 审中-公开
    人体抗原结合蛋白质，其结合了转化子分泌素KEXIN 9型

    公开(公告)号：US20160032014A1

    公开(公告)日：2016-02-04

    申请号：US14777401

    申请日：2014-03-14

    Applicant: AMGEN INC.

    Inventor： Mark Leo MICHAELS ,  Randal R. KETCHEM ,  Derek E. PIPER ,  Wei YAN ,  Chadwick Terence KING ,  Monique LaRae HOWARD

    IPC: C07K16/40

    CPC classification number: C07K16/40 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inhibiting PCSK9 binding to LDLR and having increased pH sensitivity, improved binding affinity and/or increased in vivos half life. In embodiments, the antigen binding proteins specifically bind PCSK9 and have increased pH sensitivity, improved binding affinity and/or increased in vivos half life. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind PCSK9 Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from hypercholesterolemia and related disorders or conditions.

    Abstract translation: 本发明提供与能够抑制PCSK9与LDLR结合并具有增加的pH敏感性，改善的结合亲和力和/或增加活体半衰期的抗原结合蛋白质有关或衍生的组合物和方法。 在实施方案中，抗原结合蛋白特异性结合PCSK9并具有增加的pH敏感性，改善的结合亲和力和/或增加活体半衰期。 在一些实施方案中，抗原结合蛋白是完全人，人源化或嵌合抗体，此类抗体的结合片段和衍生物，以及特异性结合PCSK9的多肽其他实施方案提供编码此类抗原结合蛋白的核酸及其片段和衍生物， 和多肽，包含此类多核苷酸的细胞，制备此类抗原结合蛋白的方法及其片段和衍生物，以及多肽，以及使用此类抗原结合蛋白，其片段及其衍生物和多肽的方法，包括治疗或诊断受试者的方法 来自高胆固醇血症和相关疾病或病症。

    Human Antigen Binding Proteins That Bind Beta-Klotho, FGF Receptors and Complexes Thereof
    8.
    发明申请
    Human Antigen Binding Proteins That Bind Beta-Klotho, FGF Receptors and Complexes Thereof 审中-公开

    公开(公告)号：US20200216546A1

    公开(公告)日：2020-07-09

    申请号：US16744734

    申请日：2020-01-16

    Applicant: Amgen, Inc.

    Inventor： Shaw-Fen Sylvia HU ,  Ian Nevin FOLTZ ,  Chadwick Terence KING ,  Yang LI ,  Taruna ARORA

    IPC: C07K16/28 ,  C07K16/18 ,  C07K14/71 ,  C07K16/40

    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.

    HUMAN ANTIGEN BINDING PROTEINS THAT BIND BETA-KLOTHO, FGF RECEPTORS AND COMPLEXES THEREOF
    9.
    发明申请
    HUMAN ANTIGEN BINDING PROTEINS THAT BIND BETA-KLOTHO, FGF RECEPTORS AND COMPLEXES THEREOF 有权
    人类抗原结合蛋白，其结合BETA-KLOTHO，FGF受体及其复合物

    公开(公告)号：US20160145351A1

    公开(公告)日：2016-05-26

    申请号：US15012939

    申请日：2016-02-02

    Applicant: Amgen Inc.

    Inventor： Shaw-Fen Sylvia HU ,  Ian Nevin FOLTZ ,  Chadwick Terence KING ,  Yang LI ,  Taruna Arora

    IPC: C07K16/40 ,  C07K16/28

    CPC classification number: C07K16/2863 ,  A61K2039/505 ,  C07K14/71 ,  C07K16/18 ,  C07K16/28 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/32 ,  C07K2317/34 ,  C07K2317/53 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/75 ,  C07K2317/92 ,  C07K2319/30

    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.

    Abstract translation: 本发明提供与抗原结合蛋白有关或衍生自抗原结合蛋白的组合物和方法激活FGF21介导的信号传导。 在实施方案中，抗原结合蛋白特异性结合（i）＆amp; bgr; -Klotho; （ii）FGFR1c，FGFR2c，FGFR3c或FGFR4; 或（iii）包含α-Klotho和FGFR1c，FGFR2c，FGFR3c和FGFR4之一的复合物。 在一些实施方案中，抗原结合蛋白诱导FGF21样信号传导。 在一些实施方案中，抗原结合蛋白是完全人，人源化或嵌合抗体，所述抗体的结合片段和衍生物，以及特异性结合（i）和/或Klotho的多肽; （ii）FGFR1c，FGFR2c，FGFR3c或FGFR4; 或（iii）包含α-Klotho和FGFR1c，FGFR2c，FGFR3c和FGFR4之一的复合物。 其它实施方案提供了编码这种抗原结合蛋白的核酸及其片段和衍生物，以及多肽，包含这种多核苷酸的细胞，制备此类抗原结合蛋白的方法及其片段和衍生物以及多肽，以及使用这些抗原结合蛋白的方法 ，其片段及其衍生物和多肽，包括治疗或诊断患有2型糖尿病，肥胖症，NASH，代谢综合征和相关疾病或病症的受试者的方法。

Patent Agency Ranking